Microneedle Patch Delivery of PLCG1-siRNA Efficient Enhanced Temozolomide Therapy for Glioblastoma.
Zhipeng YangYanjie LiuHaoyuan LiQisheng TangBiao YangZhifeng ShiYing MaoPublished in: Biomacromolecules (2024)
The blood-brain barrier (BBB) and drug resistance present challenges for chemotherapy of glioblastoma (GBM). A microneedle (MN) patch with excellent biocompatibility and biodegradability was designed to bypass the BBB and release temozolomide (TMZ) and PLCG1-siRNA directly into the tumor site for synergistic treatment of GBM. The codelivery of TMZ and PLCG1-siRNA enhanced DNA damage and apoptosis. The potential mechanism behind this enhancement is to knockdown of PLCG1 expression, which positively regulates the expression of signal transducer and activator of transcription 3 genes, thereby preventing DNA repair and enhancing the sensitivity of GBM to TMZ. The MN patch enables long-term sustainable drug release through in situ implantation and increases local drug concentrations in diseased areas, significantly extending mouse survival time compared to other drug treatment groups. MN drug delivery provides a platform for the combination treatment of GBM and other central nervous system diseases.
Keyphrases
- dna damage
- dna repair
- drug delivery
- cancer therapy
- drug release
- oxidative stress
- blood brain barrier
- poor prognosis
- squamous cell carcinoma
- emergency department
- high throughput
- cell death
- signaling pathway
- immune response
- endoplasmic reticulum stress
- binding protein
- cell proliferation
- locally advanced
- toll like receptor
- metal organic framework
- hyaluronic acid
- cell cycle arrest
- ionic liquid
- free survival